Landscapes / Companies
GI Innovation, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 in Phase 2
Drugs
5
in active trials
Trials
5 active
5 since 2021
Drugs5
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1/2 | Feb 2027Phase 1/2 trial completes | |||
| Next date | Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Metastatic Solid Tumor and 4 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Jun 2028Phase 1/2 trial completes | |||
| Next date | 30 Jun 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Metastatic Solid Tumor and 4 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Jun 2028Phase 1/2 trial completes | |||
| Next date | 30 Jun 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Metastatic Solid Tumor and 4 more | ||||
| Open drug page | |||||
— |
Phase 2 | 31 Mar 2029Phase 1/2 trial completes | |||
| Next date | 31 Mar 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Metastatic Solid Tumor and 10 more | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Janssen Research & Development |
Phase 1/2 | 31 Mar 2029Phase 1/2 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 31 Mar 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Metastatic Castration-resistant Prostate Cancer (mCRPC) | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021